The melanocortin system has five receptors, and antagonists of the central melanocortin receptors (MC3R, MC4R) are postulated to be viable therapeutics for disorders of negative energy balance such as anorexia, cachexia, and failure to thrive. Agouti-related protein (AGRP) is an antagonist of the MC3R and an antagonist/inverse agonist of the MC4R. Biophysical NMR-based structural studies have demonstrated that the active sequence of this hormone, Arg-Phe-Phe, is located on an exposed β-hairpin loop. It has previously been demonstrated that the macrocyclic octapeptide scaffold c[Pro1-Arg2-Phe3-Phe4-Asn5-Ala6-Phe7-DPro8] is 16-fold less potent than AGRP at the mouse MC4R (mMC4R). Herein it was hypothesized that the Phe7 position may be substituted to produce more potent and/or selective melanocortin receptor antagonist ligands based on this template. A 10-membered library was synthesized that substituted small (Gly), polar (Ser), acidic (Asp), basic (Lys), aliphatic (Leu, Nle, and Cha), and aromatic (Trp, Tyr, hPhe) amino acids to explore potential modifications at the Phe7 position. The most potent mMC4R antagonist contained a Nle7 substitution, was equipotent to the lead ligand 200-fold selective for the mMC4R over the mMC3R, and caused a significant increase in food intake when injected intrathecally into male mice. Three compounds possessed sigmoidal dose-response inverse agonist curves at the mMC5R, while the remaining seven decreased cAMP production from basal levels at a concentration of 100 μM. These findings will add to the knowledge base toward the development of potent and selective probes to study the role of the melanocortin system in diseases of negative energy balance and can be useful in the design of molecular probes to examine the physiological functions of the mMC5R.
The melanocortin system has five receptors, and antagonists of the central melanocortin receptors (n class="Gene">MC3R, MC4R) are postulated to be viable therapeutics for disorders of negative energy balance such as anorexia, cachexia, and failure to thrive. Agouti-related protein (AGRP) is an antagonist of the MC3R and an antagonist/inverse agonist of the MC4R. Biophysical NMR-based structural studies have demonstrated that the active sequence of this hormone, Arg-Phe-Phe, is located on an exposed β-hairpin loop. It has previously been demonstrated that the macrocyclic octapeptide scaffold c[Pro1-Arg2-Phe3-Phe4-Asn5-Ala6-Phe7-DPro8] is 16-fold less potent than AGRP at the mouseMC4R (mMC4R). Herein it was hypothesized that the Phe7 position may be substituted to produce more potent and/or selective melanocortin receptor antagonist ligands based on this template. A 10-membered library was synthesized that substituted small (Gly), polar (Ser), acidic (Asp), basic (Lys), aliphatic (Leu, Nle, and Cha), and aromatic (Trp, Tyr, hPhe) amino acids to explore potential modifications at the Phe7 position. The most potent mMC4R antagonist contained a Nle7 substitution, was equipotent to the lead ligand 200-fold selective for the mMC4R over the mMC3R, and caused a significant increase in food intake when injected intrathecally into male mice. Three compounds possessed sigmoidal dose-response inverse agonist curves at the mMC5R, while the remaining seven decreased cAMP production from basal levels at a concentration of 100 μM. These findings will add to the knowledge base toward the development of potent and selective probes to study the role of the melanocortin system in diseases of negative energy balance and can be useful in the design of molecular probes to examine the physiological functions of the mMC5R.
Authors: D Huszar; C A Lynch; V Fairchild-Huntress; J H Dunmore; Q Fang; L R Berkemeier; W Gu; R A Kesterson; B A Boston; R D Cone; F J Smith; L A Campfield; P Burn; F Lee Journal: Cell Date: 1997-01-10 Impact factor: 41.582
Authors: Mark D Ericson; Andrzej Wilczynski; Nicholas B Sorensen; Zhimin Xiang; Carrie Haskell-Luevano Journal: J Med Chem Date: 2015-04-21 Impact factor: 7.446
Authors: A A Butler; R A Kesterson; K Khong; M J Cullen; M A Pelleymounter; J Dekoning; M Baetscher; R D Cone Journal: Endocrinology Date: 2000-09 Impact factor: 4.736
Authors: Joseph C McNulty; Pilgrim J Jackson; Darren A Thompson; Biaoxin Chai; Ira Gantz; Gregory S Barsh; Philip E Dawson; Glenn L Millhauser Journal: J Mol Biol Date: 2005-01-25 Impact factor: 5.469
Authors: Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano Journal: J Med Chem Date: 2016-03-29 Impact factor: 7.446
Authors: D Lu; D Willard; I R Patel; S Kadwell; L Overton; T Kost; M Luther; W Chen; R P Woychik; W O Wilkison Journal: Nature Date: 1994-10-27 Impact factor: 49.962
Authors: Katlyn A Fleming; Katie T Freeman; Mike D Powers; Radleigh G Santos; Ginamarie Debevec; Marc A Giulianotti; Richard A Houghten; Skye R Doering; Clemencia Pinilla; Carrie Haskell-Luevano Journal: J Med Chem Date: 2019-02-28 Impact factor: 7.446
Authors: Mark D Ericson; Zoe M Koerperich; Katie T Freeman; Katlyn A Fleming; Carrie Haskell-Luevano Journal: ACS Chem Neurosci Date: 2018-07-20 Impact factor: 4.418
Authors: Zoe M Koerperich; Mark D Ericson; Katie T Freeman; Robert C Speth; Irina D Pogozheva; Henry I Mosberg; Carrie Haskell-Luevano Journal: J Med Chem Date: 2020-01-06 Impact factor: 7.446
Authors: Cody J Lensing; Katie T Freeman; Sathya M Schnell; Robert C Speth; Adam T Zarth; Carrie Haskell-Luevano Journal: J Med Chem Date: 2018-05-09 Impact factor: 7.446
Authors: Mark D Ericson; Erica M Haslach; Sathya M Schnell; Katie T Freeman; Zhimin M Xiang; Frederico P Portillo; Robert Speth; Sally A Litherland; Carrie Haskell-Luevano Journal: ACS Chem Neurosci Date: 2021-01-20 Impact factor: 4.418